Latest market price
45.55
+1.21+2.73%
SNYQT45Sanofi·NASDAQ
45.55+2.73%
News
Up 2.7% — Sanofi Q3 Earnings Call Highlights (marketbeat.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index—P/E78.53EPS (ttm)0.58Insider Own—Shs Outstand2.40BPerf Week9.00%
Market Cap109.14BForward P/E9.29EPS next Y4.90Insider Trans—Shs Float2.16BPerf Month14.10%
Enterprise Value128.55BPEG10.36EPS next Q1.20Short Float0.54%Perf Quarter6.72%
Income4.63BP/S1.91EPS this Y6.61%Short Ratio3.91Perf Half Y5.07%
Sales57.07BP/B1.37EPS next Y6.55%ROA3.07%Short Interest11.61MPerf YTD-6.00%
Book/sh33.14P/C15.06EPS next 5Y7.58%ROE5.52%52W High52.68 -13.53%Perf Year-10.58%
Cash/sh3.02P/FCF7.95EPS past 3/5Y2.58% -8.40%ROIC7.41%52W Low39.07 16.59%Perf 3Y-14.59%
Dividend Est.2.42 (5.31%)EV/EBITDA7.46Sales past 3/5Y7.30% 4.34%Gross Margin72.77%Volatility2.00% 1.74%Perf 5Y-8.52%
Dividend TTM2.42 (5.31%)EV/Sales2.25EPS Y/Y TTM-86.28%Oper. Margin20.58%ATR (14)0.92Perf 10Y20.66%
Dividend Ex-DateMay 04, 2026Quick Ratio0.23Sales Y/Y TTM21.38%Profit Margin8.09%RSI (14)72.82Recom2.59
Dividend Gr. 3/5Y2.41% 4.60%Current Ratio0.99EPS Q/Q20.00%SMA2010.55%Beta0.25Target Price49.00
Payout124.38%Debt/Eq0.34Sales Q/Q17.52%SMA507.94%Rel Volume2.34Prev Close44.34
Employees76,493LT Debt/Eq0.23EarningsFeb 04SMA2002.79%Avg Volume3.15MPrice45.55
IPO DateJul 01, 2002Option/ShortYes / YesEPS/Sales Surpr.30.77% 14.46%Net Debt/EBITDA1.13Volume7,368,656Change2.73%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-08-26ReiteratedMorgan StanleyEqual Weight$52 → $49
May-01-26DowngradeMorgan StanleyOverweight → Equal Weight$56 → $52
Apr-20-26ReiteratedBNP Paribas$50
Apr-20-26DowngradeExane BNP ParibasOutperform → Neutral
Feb-12-26DowngradeB of A SecuritiesBuy → Neutral
Jan-16-26DowngradeUBSBuy → Neutral
Jan-06-26DowngradeBarclaysOverweight → Equal Weight
Dec-09-25DowngradeGuggenheimBuy → Neutral
Dec-08-25DowngradeJP MorganOverweight → Neutral
Sep-08-25UpgradeMorgan StanleyEqual Weight → Overweight
Latest News· Times ET
Oct-30-26
Oct-30-2612:17PM
Oct-27-26
Oct-26-26
Oct-20-26
Oct-19-26
Oct-15-26
Oct-14-26
Company

Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue57,06652,70247,91345,016—————
Cost of Goods Sold Incl. D&A15,39514,72114,28613,659—————
Gross Profit41,67037,98133,62631,357—————
Selling, General and Administrative Excl. Other11,45311,5549,9359,662—————
Research and Development9,4528,8478,0007,038—————
Other Operating Expense12,3116,7537,8457,129—————
Operating Income8,45310,8277,8467,528—————
Interest Expense690706674555—————
Unusual Expense
—————————
Non-Operating Income (Expense)-1,687-3,329139-359—————
Net Income Before Taxes6,0766,7917,3116,614—————
Income Taxes1,4061,1771,3031,100—————
Consolidated Net Income4,6318,8146,0155,841—————
Net Income From Continuing Operations4,6705,6156,0095,514—————
Net Income4,6318,8146,0155,841—————
EPS (Recurring)0.573.612.372.33—————
EPS (Basic, Before Extraordinaries)0.573.612.372.33—————
EPS (Diluted)0.583.612.372.33—————
EBITDA17,23114,07811,93712,320—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio78.5313.4220.3621.38—————
Price To Sales Ratio1.912.242.522.77—————
Gross Margin73.0272.0770.1869.66—————
Operating Margin14.8120.5416.3816.72—————
Net Margin8.1216.7212.5512.98—————
Shares Outstanding2,3932,4412,5032,503—————
Market Capitalization109,001118,291120,720124,474—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.